In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price target of $80.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Ulz has given his Buy rating due to a combination of factors, primarily focusing on the promising data presented by Rhythm Pharmaceuticals at recent conferences. The company showcased real-world results from patients treated with setmelanotide, which demonstrated significant reductions in BMI and hunger scores over time, particularly in those with acquired or congenital hypothalamic obesity.
These findings were consistent with previous data, reinforcing the drug’s potential effectiveness in a real-world setting. Furthermore, the absence of new safety concerns and the anticipation of regulatory filings and further clinical data in the near future contribute to a positive outlook for Rhythm Pharmaceuticals. These elements collectively support the Buy rating, as they suggest a strong potential for setmelanotide to address unmet needs in the treatment of hypothalamic obesity.
According to TipRanks, Ulz is an analyst with an average return of -6.1% and a 37.75% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Rhythm Pharmaceuticals.
In another report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.